Immunotherapy and Systemic Treatment of Cutaneous Squamous Cell Carcinoma
Keywords:
cutaneous squamous cell carcinoma, systemic therapies, immunotherapy, tumor response, cSCC, advanced cSCCAbstract
Cutaneous squamous cell carcinomas (cSCC) represent one of the most diagnosed non-melanoma skin cancers and its incidence is increasing globally. Whereas early stage and low risk cSCC is typically treated with surgery, and in some cases other localized therapeutic modalities, locally advanced or metastatic cSCC is a cause of significant morbidity and mortality that requires a different approach to therapy. Therapeutic attempts at treating advanced cSCC include a multi-disciplinary approach with considerations for surgery, radiation, and systemic therapies. In this review, we will discuss the various systemic therapies that have been trialed for advanced cSCC, beginning with the early cytotoxic and platinum-based agents as well as their corresponding limitations. We will then review the targeted approaches using EGFR inhibitors prior to discussing the more recent immunotherapeutics that have shown good tumor responses in this often-lethal disease.
References
Lomas A, Leonardi‐Bee J, Bath‐Hextall F. A systematic review of worldwide incidence of nonmelanoma skin cancer. Br J Dermatol. (1951). 2012;166(5):1069-80. DOI: 10.1111/j.1365-2133.2012.10830.x. PMID: 22251204.
Perera E, Gnaneswaran N, Staines C, Win AK, Sinclair R. Incidence and prevalence of non‐melanoma skin cancer in Australia: A systematic review. Australas J Dermatol. 2015;56(4):258-67. DOI: 10.1111/ajd.12282. PMID: 25716064.
Brewster DH, Bhatti LA, Inglis JHC, Nairn ER, Doherty VR. Recent trends in incidence of nonmelanoma skin cancers in the East of Scotland, 1992–2003. Br J Dermatol. 2007;156(6):1295-300. DOI: 10.1111/j.1365-2133.2007.07892.x. PMID: 17535229.
Andersson EM, Paoli J, Wastensson G. Incidence of cutaneous squamous cell carcinoma in coastal and inland areas of Western Sweden. Cancer Epidemiol. 2011;35(6):e69-74. DOI: 10.1016/j.canep.2011.05.006. PMID: 21840282.
Katalinic A, Kunze U, Schäfer T. Epidemiology of cutaneous melanoma and non-melanoma skin cancer in Schleswig-Holstein, Germany: incidence, clinical subtypes, tumour stages and localization (epidemiology of skin cancer). Br J Dermatol. 2003;149(6):1200-6. DOI: 10.1111/j.1365-2133.2003.05554.x. PMID: 14674897.
Staples MP, Elwood M, Burton RC, Williams JL, Marks R, Giles GG. Non-melanoma skin cancer in Australia: the 2002 national survey and trends since 1985. Med J Aust. 2006;184(1):6-10. DOI: 10.5694/j.1326-5377.2006.tb00086.x. PMID: 16398622.
Muzic JG, Schmitt AR, Wright AC, et al. Incidence and Trends of Basal Cell Carcinoma and Cutaneous Squamous Cell Carcinoma: A Population-Based Study in Olmsted County, Minnesota, 2000 to 2010. Mayo Clin Proc. 2017;92(6):890-898. DOI:10.1016/j.mayocp.2017.02.015. PMID: 28522111.
Rogers HW, Weinstock MA, Feldman SR, Coldiron BM. Incidence Estimate of Nonmelanoma Skin Cancer (Keratinocyte Carcinomas) in the U.S. Population, 2012. JAMA Dermatol. 2015;151(10):1081-1086. DOI:10.1001/jamadermatol.2015.1187 PMID: 25928283.
Lansbury L, Bath-Hextall F, Perkins W, Stanton W, Leonardi-Bee J. Interventions for non-metastatic squamous cell carcinoma of the skin: systematic review and pooled analysis of observational studies. BMJ. 2013;347:f6153. DOI: 10.1136/bmj.f6153. PMID: 24191270.
Kim JYS, Kozlow JH, Mittal B, et al. Guidelines of care for the management of cutaneous squamous cell carcinoma. J Am Acad Dermatol. 2018;78(3):560-578. DOI: 10.1016/j.jaad.2017.10.007. PMID: 29331386.
Schmults CD, Karia PS, Carter JB, Han J, Qureshi AA. Factors predictive of recurrence and death from cutaneous squamous cell carcinoma: a 10-year, single-institution cohort study. JAMA Dermatol. 2013;149(5):541-7. DOI: 10.1001/jamadermatol.2013.2139. PMID: 23677079.
DeConti RC. Chemotherapy of squamous cell carcinoma of the skin. Semin Oncol. 2012;39(2):145-9. DOI: 10.1053/j.seminoncol.2012.01.002. PMID: 22484186.
Sadek H, Azli N, Wendling JL, et al. Treatment of advanced squamous cell carcinoma of the skin with cisplatin, 5-fluorouracil, and bleomycin. Cancer. 1990;66(8):1692-6. DOI: 10.1002/1097-0142(19901015)66:8<1692::aid-cncr2820660807>3.0.co;2-y. PMID: 1698529.
Guthrie TH Jr, Porubsky ES, Luxenberg MN, Shah KJ, Wurtz KL, Watson PR. Cisplatin-based chemotherapy in advanced basal and squamous cell carcinomas of the skin: results in 28 patients including 13 patients receiving multimodality therapy. J Clin Oncol. 1990;8(2):342-6. DOI: 10.1200/JCO.1990.8.2.342. PMID: 2405109.
Nottage MK, Lin C, Hughes BG, et al. Prospective study of definitive chemoradiation in locally or regionally advanced squamous cell carcinoma of the skin. Head Neck. 2017;39(4):679-683. DOI: 10.1002/hed.24662. PMID: 28032670.
Chatelut E, Delord JP, Canal P. Toxicity patterns of cytotoxic drugs. Invest New Drugs. 2003;21(2):141-8. DOI: 10.1023/a:1023565227808. PMID: 12889735.
Galbiati D, Cavalieri S, Alfieri S, et al. Activity of platinum and cetuximab in cutaneous squamous cell cancer not amenable to curative treatment. Drugs Context. 2019;8:212611. DOI: 10.7573/dic.212611. PMID: 32158481.
Sabbah DA, Hajjo R, Sweidan K. Review on Epidermal Growth Factor Receptor (EGFR) Structure, Signaling Pathways, Interactions, and Recent Updates of EGFR Inhibitors. Curr Top Med Chem. 2020;20(10):815-834. DOI: 10.2174/1568026620666200303123102. PMID: 32124699.
Chen J, Zeng F, Forrester SJ, Eguchi S, Zhang MZ, Harris RC. Expression and Function of the Epidermal Growth Factor Receptor in Physiology and Disease. Physiol Rev. 2016;96(3):1025-1069. DOI: 10.1152/physrev.00030.2015. PMID: 33003261.
Oda K, Matsuoka Y, Funahashi A, Kitano H. A comprehensive pathway map of epidermal growth factor receptor signaling. Mol Syst Biol. 2005;1:2005.0010. DOI: 10.1038/msb4100014. PMID: 16729045.
Uribe P, Gonzalez S. Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy. Pathol Res Pract. 2011;207(6):337-42. DOI: 10.1016/j.prp.2011.03.002. PMID: 21531084.
Shimizu T, Izumi H, Oga A, et al. Epidermal growth factor receptor overexpression and genetic aberrations in metastatic squamous-cell carcinoma of the skin. Dermatology. 2001;202(3):203-6. DOI: 10.1159/000051637. PMID: 11385224.
Maubec E, Petrow P, Scheer-Senyarich I, et al. Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin. J Clin Oncol. 2011;29(25):3419-26. DOI: 10.1200/JCO.2010.34.1735. PMID: 21810686.
Montaudié H, Viotti J, Combemale P, et al. Cetuximab is efficient and safe in patients with advanced cutaneous squamous cell carcinoma: a retrospective, multicentre study. Oncotarget. 2020;11(4):378-385. DOI: 10.18632/oncotarget.27434. PMID: 32064041.
Foote MC, McGrath M, Guminski A, et al. Phase II study of single-agent panitumumab in patients with incurable cutaneous squamous cell carcinoma. Ann Oncol. 2014;25(10):2047-2052. DOI: 10.1093/annonc/mdu368. PMID: 25091317.
William WN Jr, Feng L, Ferrarotto R, et al. Gefitinib for patients with incurable cutaneous squamous cell carcinoma: A single-arm phase II clinical trial. J Am Acad Dermatol. 2017;77(6):1110-1113.e2. DOI: 10.1016/j.jaad.2017.07.048. PMID: 28964539.
Lewis CM, Glisson BS, Feng L, et al. A phase II study of gefitinib for aggressive cutaneous squamous cell carcinoma of the head and neck. Clin Cancer Res. 2012 ;18(5):1435-46. DOI: 10.1158/1078-0432.CCR-11-1951. PMID: 22261807
Gold KA, Kies MS, William WN Jr, Johnson FM, Lee JJ, Glisson BS. Erlotinib in the treatment of recurrent or metastatic cutaneous squamous cell carcinoma: A single-arm phase 2 clinical trial. Cancer. 2018;124(10):2169-2173. DOI: 10.1002/cncr.31346. PMID: 29579331; PMCID: PMC5935588.
Heath CH, Deep NL, Nabell L, et al. Phase 1 study of erlotinib plus radiation therapy in patients with advanced cutaneous squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2013;85(5):1275-81. DOI: 10.1016/j.ijrobp.2012.09.030. PMID: 23182701.
Strickley JD, Spalding AC, Haeberle MT, Brown T, Stevens DA, Jung J. Metastatic squamous cell carcinoma of the skin with clinical response to lapatinib. Exp Hematol Oncol. 2018;7:20. DOI: 10.1186/s40164-018-0111-z. PMID: 30181930.
Jenni D, Karpova MB, Mühleisen B, et al. A prospective clinical trial to assess lapatinib effects on cutaneous squamous cell carcinoma and actinic keratosis. ESMO Open. 2016;1(1):e000003. DOI: 10.1136/esmoopen-2015-000003. PMID: 27843579.
Chanprapaph K, Vachiramon V, Rattanakaemakorn P. Epidermal growth factor receptor inhibitors: a review of cutaneous adverse events and management. Dermatol Res Pract. 2014;2014:734249. DOI: 10.1155/2014/734249. PMID: 2472394.
Wacker B, Nagrani T, Weinberg J, Witt K, Clark G, Cagnoni PJ. Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res. 2007;13(13):3913-21. DOI: 10.1158/1078-0432.CCR-06-2610. PMID: 17606725.
Hirsh V. Managing treatment-related adverse events associated with egfr tyrosine kinase inhibitors in advanced non-small-cell lung cancer. Curr Oncol. 2011;18(3):126-38. DOI: 10.3747/co.v18i3.877. PMID: 21655159.
Wheeler DL, Dunn EF, Harari PM. Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat Rev Clin Oncol. 2010;7(9):493-507. DOI: 10.1038/nrclinonc.2010.97. PMID: 20551942.
Zhao B, Wang L, Qiu H, et al. Mechanisms of resistance to anti-EGFR therapy in colorectal cancer. Oncotarget. 2017;8(3):3980-4000. DOI: 10.18632/oncotarget.14012. PMID: 28002810.
Sforza V, Martinelli E, Ciardiello F, et al. Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer. World J Gastroenterol. 2016;22(28):6345-61. DOI: 10.3748/wjg.v22.i28.6345. PMID: 27605871.
Lovly CM, Horn L. Strategies for overcoming EGFR resistance in the treatment of advanced-stage NSCLC. Curr Treat Options Oncol. 2012;13(4):516-26. DOI: 10.1007/s11864-012-0204-6. PMID: 22833206.
Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med. 2003;348(17):1681-91. DOI: 10.1056/NEJMra022137. PMID: 12711744.
Berg D, Otley CC. Skin cancer in organ transplant recipients: Epidemiology, pathogenesis, and management. J Am Acad Dermatol. 2002;47(1):1-17; quiz 18-20. DOI: 10.1067/mjd.2002.125579. PMID: 12077575.
Kripke ML. Ultraviolet radiation and immunology: something new under the sun--presidential address. Cancer Res. 1994;54(23):6102-5. PMID: 7954455.
Pickering CR, Zhou JH, Lee JJ, et al. Mutational landscape of aggressive cutaneous squamous cell carcinoma. Clin Cancer Res. 2014;20(24):6582-92. DOI: 10.1158/1078-0432.CCR-14-1768. PMID: 25303977.
Wu Y, Xu J, Du C, et al. The Predictive Value of Tumor Mutation Burden on Efficacy of Immune Checkpoint Inhibitors in Cancers: A Systematic Review and Meta-Analysis. Front Oncol. 2019;9:1161. DOI: 10.3389/fonc.2019.01161. PMID: 31750249.
Bottomley MJ, Thomson J, Harwood C, Leigh I. The Role of the Immune System in Cutaneous Squamous Cell Carcinoma. Int J Mol Sci. 2019;20(8):2009. DOI: 10.3390/ijms20082009. PMID: 31022866.
Chraa D, Naim A, Olive D, Badou A. T lymphocyte subsets in cancer immunity: Friends or foes. J Leukoc Biol. 2019;105(2):243-255. DOI: 10.1002/JLB.MR0318-097R. PMID: 30387907.
Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455-65. DOI: 10.1056/NEJMoa1200694. PMID: 22658128.
Robainas M, Otano R, Bueno S, Ait-Oudhia S. Understanding the role of PD-L1/PD1 pathway blockade and autophagy in cancer therapy. Onco Targets Ther. 2017;10:1803-1807. DOI: 10.2147/OTT.S132508. PMID: 28367063.
Akinleye A, Rasool Z. Immune checkpoint inhibitors of PD-L1 as cancer therapeutics. J Hematol Oncol. 2019;12(1):92. DOI: 10.1186/s13045-019-0779-5. PMID: 31488176.
Riley JL. PD-1 signaling in primary T cells. Immunol Rev. 2009;229(1):114-25. DOI: 10.1111/j.1600-065X.2009.00767.x. PMID: 19426218.
Migden MR, Rischin D, Schmults CD, et al. PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma. N Engl J Med. 2018;379(4):341-351. DOI: 10.1056/NEJMoa1805131. PMID: 29863979.
Rischin D, Migden MR, Lim AM, et al. Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing. J Immunother Cancer. 2020;8(1):e000775. DOI: 10.1136/jitc-2020-000775. PMID: 32554615.
Migden MR, Khushalani NI, Chang ALS, et al. Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial. Lancet Oncol. 2020;21(2):294-305. DOI: 10.1016/S1470-2045(19)30728-4. PMID: 31952975.
Grob JJ, Gonzalez R, Basset-Seguin N, et al. Pembrolizumab Monotherapy for Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: A Single-Arm Phase II Trial (KEYNOTE-629). J Clin Oncol. 2020;38(25):2916-2925. DOI: 10.1200/JCO.19.03054. Epub 2020 Jul 16. PMID: 32673170.
Maubec E, Boubaya M, Petrow P, et al. Phase II Study of Pembrolizumab As First-Line, Single-Drug Therapy for Patients With Unresectable Cutaneous Squamous Cell Carcinomas. J Clin Oncol. 2020;38(26):3051-3061. DOI: 10.1200/JCO.19.03357. PMID: 32730186.
Spiers L, Coupe N, Payne M. Toxicities associated with checkpoint inhibitors-an overview. Rheumatology. 2019;58(Suppl 7):vii7-vii16. DOI: 10.1093/rheumatology/kez418. PMID: 31816085.
Ribas A, Hamid O, Daud A, et al. Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. JAMA. 2016;315(15):1600-9. DOI: 10.1001/jama.2016.4059. PMID: 27092830.
Nowicki TS, Hu-Lieskovan S, Ribas A. Mechanisms of Resistance to PD-1 and PD-L1 Blockade. Cancer J. 2018;24(1):47-53. DOI: 10.1097/PPO.0000000000000303. PMID: 29360728.
ClinicalTrials.gov [Internet]. Baltimore (MD):National Library of Medicine (US). 2000 Feb 29 - . Identifier NCT03889912 , Pre-Operative Cemiplimab Administered Intralesionally for Patients With Recurrent Cutaneous Squamous Cell Carcinoma ; 2019 March 26. Accessed April 15,2021; https://clinicaltrials.gov/ct2/show/NCT03889912.
Taube JM, Klein A, Brahmer JR, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res. 2014;20(19):5064-74. DOI: 10.1158/1078-0432.CCR-13-3271. PMID: 24714771.
Tsoukalas N, Kiakou M, Tsapakidis K, et al. PD-1 and PD-L1 as immunotherapy targets and biomarkers in non-small cell lung cancer. J BUON. 2019;24(3):883-888. PMID: 31424637.
Fischer S, Hasan Ali O, Jochum W, Kluckert T, Flatz L, Siano M. Anti-PD-1 Therapy Leads to Near-Complete Remission in a Patient with Metastatic Basal Cell Carcinoma. Oncol Res Treat. 2018;41(6):391-394. DOI: 10.1159/000487084. PMID: 29734143.
Shen X, Zhao B. Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis. BMJ. 2018;362:k3529. DOI: 10.1136/bmj.k3529. PMID: 30201790.
Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012;366(10):883-892. DOI: 10.1056/NEJMoa1113205. 2012 Sep 6;367(10):976. PMID: 22397650.
Krishnamurthy A, Jimeno A. Atezolizumab: A novel PD-L1 inhibitor in cancer therapy with a focus in bladder and non-small cell lung cancers. Drugs Today. 2017;53(4):217-237. DOI: 10.1358/dot.2017.53.4.2589163. PMID: 28492290.
Lipson EJ, Forde PM, Hammers HJ, Emens LA, Taube JM, Topalian SL. Antagonists of PD-1 and PD-L1 in Cancer Treatment. Semin Oncol. 2015;42(4):587-600. DOI: 10.1053/j.seminoncol.2015.05.013. PMID: 26320063.
Bayan CY, Lopez AT, Gartrell RD, et al. The Role of Oncolytic Viruses in the Treatment of Melanoma. Curr Oncol Rep. 2018;20(10):80. DOI: 10.1007/s11912-018-0729-3. PMID: 30145781.
Middleton MR, Sacco JJ, Merchan JR, et al. An open label, multicenter, phase I/II study of RP1 as a single agent and in combination with PD1 blockade in patients with solid tumors. Journal of Clinical Oncology 2019:15_suppl, TPS2671-TPS2671.
Phan GQ, Yang JC, Sherry RM, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A. 2003;100(14):8372-7. DOI: 10.1073/pnas.1533209100. PMID: 12826605.
Middleton G. Beyond Ipilimumab: a review of immunotherapeutic approaches in clinical trials in melanoma, Immunotherapy Advances. ltaa010.2021;1(1). DOI:10.1093/immadv/ltaa010.
Day F, Kumar M, Fenton L, Gedye C. Durable Response of Metastatic Squamous Cell Carcinoma of the Skin to Ipilimumab Immunotherapy. J Immunother. 2017;40(1):36-38. DOI: 10.1097/CJI.0000000000000146. PMID: 27684455.
Chen J, Li S, Yao Q, et al. The efficacy and safety of combined immune checkpoint inhibitors (nivolumab plus ipilimumab): a systematic review and meta-analysis. World J Surg Oncol. 2020;18(1):150. DOI: 10.1186/s12957-020-01933-5. PMID: 32620130.
ClinicalTrials.gov [Internet]. Baltimore (MD):National Library of Medicine (US). 2000 Feb 29 - . Identifier NCT04620200, Neo-adjuvant Nivolumab or Nivolumab With Ipilimumab in Advanced Cutaneous Squamous Cell Carcinoma Prior to Surgery (MATISSE); 2020, November 6. Accessed April 15,2021. https://clinicaltrials.gov/ct2/show/NCT04620200.
Picard A, Pedeutour F, Peyrade F, et al. Association of Oncogenic Mutations in Patients With Advanced Cutaneous Squamous Cell Carcinomas Treated With Cetuximab. JAMA Dermatol. 2017;153(4):291-298. DOI: 10.1001/jamadermatol.2017.0270. PMID: 28259104.
Nishino M, Ramaiya NH, Hatabu H, Hodi FS. Monitoring immune-checkpoint blockade: response evaluation and biomarker development. Nat Rev Clin Oncol. 2017;14(11):655-668. DOI: 10.1038/nrclinonc.2017.88. PMID: 28653677.
Guthrie TH Jr, McElveen LJ, Porubsky ES, Harmon JD. Cisplatin and doxorubicin. An effective chemotherapy combination in the treatment of advanced basal cell and squamous carcinoma of the skin. Cancer. 1985;55(8):1629-32. DOI: 10.1002/1097-0142(19850415)55:8<1629::aid-cncr2820550802>3.0.co;2-i. PMID: 4038911.
Khansur T, Kennedy A. Cisplatin and 5-fluorouracil for advanced locoregional and metastatic squamous cell carcinoma of the skin. Cancer. 1991;67(8):2030-2. DOI: 10.1002/1097-0142(19910415)67:8<2030::aid-cncr2820670803>3.0.co;2-k. PMID: 2004320.
Merimsky O, Neudorfer M, Spitzer E, Chaitchik S. Salvage cisplatin and adriamycin for advanced or recurrent basal or squamous cell carcinoma of the face. Anticancer Drugs. 1992;3(5):481-4. DOI: 10.1097/00001813-199210000-00006. PMID: 1450442.
Cartei G, Cartei F, Interlandi G, et al. Oral 5-fluorouracil in squamous cell carcinoma of the skin in the aged. Am J Clin Oncol. 2000;23(2):181-4. DOI: 10.1097/00000421-200004000-00015. PMID: 10776981.
Shin DM, Glisson BS, Khuri FR, et al. Phase II and biologic study of interferon alfa, retinoic acid, and cisplatin in advanced squamous skin cancer. J Clin Oncol. 2002;20(2):364-70. DOI: 10.1200/JCO.2002.20.2.364. PMID: 11786562.
Fujisawa Y, Umebayashi Y, Ichikawa E, Kawachi Y, Otsuka F. Chemoradiation using low-dose cisplatin and 5-fluorouracil in locally advanced squamous cell carcinoma of the skin: a report of two cases. J Am Acad Dermatol. 2006;55(5 Suppl):S81-5. DOI: 10.1016/j.jaad.2005.12.035. PMID: 17052540.
Hillen U, Leiter U, Haase S, et al. Dermatologic Cooperative Oncology Group (DeCOG). Advanced cutaneous squamous cell carcinoma: A retrospective analysis of patient profiles and treatment patterns-Results of a non-interventional study of the DeCOG. Eur J Cancer. 2018;96:34-43. DOI: 10.1016/j.ejca.2018.01.075. PMID: 29665511.
Preneau S, Rio E, Brocard A, et al. Efficacy of cetuximab in the treatment of squamous cell carcinoma. J Dermatolog Treat. 2014;25(5):424-7. DOI: 10.3109/09546634.2012.751481. PMID: 23167307.
Reigneau M, Robert C, Routier E, et al. Efficacy of neoadjuvant cetuximab alone or with platinum salt for the treatment of unresectable advanced nonmetastatic cutaneous squamous cell carcinomas. Br J Dermatol. 2015 Aug;173(2):527-34. DOI: 10.1111/bjd.13741. PMID: 25704233.
In GK, Vaidya P, Filkins A, et al. PD-1 inhibition therapy for advanced cutaneous squamous cell carcinoma: a retrospective analysis from the University of Southern California. J Cancer Res Clin Oncol. 2021;147(6):1803-1811. DOI: 10.1007/s00432-020-03458-6. PMID: 33210210.
Salzmann M, Leiter U, Loquai C, et al. Programmed cell death protein 1 inhibitors in advanced cutaneous squamous cell carcinoma: real-world data of a retrospective, multicenter study. Eur J Cancer. 2020;138:125-132. DOI: 10.1016/j.ejca.2020.07.029. PMID: 32882466.
Eton O, Hsu E, Patel A, et al. Anti-EGFR antibody added to ongoing anti-PD-1 antibody treatment for metastatic cutaneous squamous cell carcinoma of the face: two case reports. Journal for ImmunoTherapy of Cancer. 2020;8. DOI: 10.1136/jitc-2020-SITC2020.0467.
Published
Issue
Section
License
Copyright (c) 2021 Nader Aboul-Fettouh, Daniel Morse, Jigar Patel, Michael R. Migden
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Dermatology Practical & Conceptual applies a Creative Commons Attribution License (CCAL) to all works we publish (http://creativecommons.org/licenses/by-nc/4.0/). Authors retain the copyright for their published work.
How to Cite
Share
